Literature DB >> 10653281

Genes and mechanisms involved in beta-amyloid generation and Alzheimer's disease.

H Steiner1, A Capell, U Leimer, C Haass.   

Abstract

Alzheimer's disease is characterized by the invariable accumulation of senile plaques that are predominantly composed of amyloid beta-peptide (Abeta). Abeta is generated by proteolytic processing of the beta-amyloid precursor protein (betaAPP) involving the combined action of beta- and gamma-secretase. Cleavage within the Abeta domain by alpha-secretase prevents Abeta generation. In some very rare cases of familial AD (FAD), mutations have been identified within the betaAPP gene. These mutations are located close to or at the cleavage sites of the secretases and pathologically effect betaAPP processing by increasing Abeta production, specifically its highly amyloidogenic 42 amino acid variant (Abeta42). Most of the mutations associated with FAD have been identified in the two presenilin (PS) genes, particularly the PS1 gene. Like the mutations identified within the betaAPP gene, mutations in PS1 and PS2 cause the increased generation of Abeta42. PS1 has been shown to be functionally involved in Notch signaling, a key process in cellular differentation, and in betaAPP processing. A gene knock out of PS1 in mice leads to an embryonic lethal phenotype similar to that of mice lacking Notch. In addition, absence of PS1 results in reduced gamma-secretase cleavage and leads to an accumulation of betaAPP C-terminal fragments and decreased amounts of Abeta. Recent work may suggest that PS1 could be the gamma-secretase itself, exhibiting the properties of a novel aspartyl protease. Mutagenesis of either of two highly conserved intramembraneous aspartate residues of PS1 leads to reduced Abeta production as observed in the PS1 knockout. A corresponding mutation in PS2 interfered with betaAPP processing and Notch signaling suggesting a functional redundancy of both presenilins. In this issue, some of the recent work on the molecular mechanisms involved in Alzheimer's disease (AD) as well as novel diagnostic approaches and risk factors for AD will be discussed. In the first article, we like to give an overview on mechanisms involved in the proteolytic generation of Amyloid beta-peptide (Abeta), the major pathological player of this devastating disease. In the second part of this article recent results will be described, which demonstrate an unexpected biological and pathological function of an AD associated gene.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10653281     DOI: 10.1007/s004060050098

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  12 in total

1.  Progress in transthyretin fibrillogenesis research strengthens the amyloid hypothesis.

Authors:  A Chakrabartty
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

Review 2.  Mechanisms of neural and behavioral dysfunction in Alzheimer's disease.

Authors:  Daniel W Wesson; Ralph A Nixon; Efrat Levy; Donald A Wilson
Journal:  Mol Neurobiol       Date:  2011-03-22       Impact factor: 5.590

3.  Is Beta-Amyloid Accumulation a Cause or Consequence of Alzheimer's Disease?

Authors:  Shaoxun Wang; Paige N Mims; Richard J Roman; Fan Fan
Journal:  J Alzheimers Parkinsonism Dement       Date:  2016-11-17

4.  Population PKPD modeling of BACE1 inhibitor-induced reduction in Aβ levels in vivo and correlation to in vitro potency in primary cortical neurons from mouse and guinea pig.

Authors:  Juliette Janson; Susanna Eketjäll; Karin Tunblad; Fredrik Jeppsson; Stefan Von Berg; Camilla Niva; Ann-Cathrin Radesäter; Johanna Fälting; Sandra A G Visser
Journal:  Pharm Res       Date:  2013-10-03       Impact factor: 4.200

5.  Divergent pathways mediate spine alterations and cell death induced by amyloid-beta, wild-type tau, and R406W tau.

Authors:  Christian Tackenberg; Roland Brandt
Journal:  J Neurosci       Date:  2009-11-18       Impact factor: 6.167

Review 6.  Advances in development of fluorescent probes for detecting amyloid-β aggregates.

Authors:  Ming-Ming Xu; Wen-Ming Ren; Xi-Can Tang; You-Hong Hu; Hai-Yan Zhang
Journal:  Acta Pharmacol Sin       Date:  2016-03-21       Impact factor: 6.150

7.  Regulated proteolysis of NOTCH2 and NOTCH3 receptors by ADAM10 and presenilins.

Authors:  Arjan J Groot; Roger Habets; Sanaz Yahyanejad; Caroline M Hodin; Karina Reiss; Paul Saftig; Jan Theys; Marc Vooijs
Journal:  Mol Cell Biol       Date:  2014-05-19       Impact factor: 4.272

Review 8.  Neuronal autophagy and neurodegenerative diseases.

Authors:  Jin H Son; Jung Hee Shim; Kyung Hee Kim; Ji Young Ha; Ji Young Han
Journal:  Exp Mol Med       Date:  2012-02-29       Impact factor: 8.718

9.  AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics.

Authors:  Susanna Eketjäll; Juliette Janson; Karin Kaspersson; Anna Bogstedt; Fredrik Jeppsson; Johanna Fälting; Samantha Budd Haeberlein; Alan R Kugler; Robert C Alexander; Gvido Cebers
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

10.  Protein-Induced Pluripotent Stem Cells Ameliorate Cognitive Dysfunction and Reduce Aβ Deposition in a Mouse Model of Alzheimer's Disease.

Authors:  Moon-Yong Cha; Yoo-Wook Kwon; Hyo-Suk Ahn; Hyobin Jeong; Yong Yook Lee; Minho Moon; Sung Hoon Baik; Dong Kyu Kim; Hyundong Song; Eugene C Yi; Daehee Hwang; Hyo-Soo Kim; Inhee Mook-Jung
Journal:  Stem Cells Transl Med       Date:  2016-08-15       Impact factor: 6.940

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.